Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Any time

2019 ( 1 )

2018 ( 1 )

2016 ( 1 )

2015 ( 16 )

Custom range...

Search Results: 1 - 10 of 702 matches for " Jungsil Ro "
All listed articles are free for downloading (OA Articles)
Page 1 /702
Display every page Item
Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases
In Park, Jungsil Ro, Byung Nam, Youngmi Kwon, Keun Lee
BMC Cancer , 2009, DOI: 10.1186/1471-2407-9-154
Abstract: Of 317 patients with initial bone metastasis and known breast cancer subtypes, 230 patients (72.6%) had hormone receptor (HR) positive tumors, and 87 patients (27.4%) had HR negative tumors. We assessed the primary outcome of overall survival (OS), after adjusting for other factors, comparing a group that received bisphosphonates (BPs) with a group that did not receive it.87.8% of HR positive and 69.0% of HR negative patients received BPs with a median number of 17.7 cycles. Although BPs treatment made no survival benefit in HR positive group, HR negative patients showed a significant prolonged survival when they received BPs treatment (hazard ratio = 0.56 [95% CI 0.34 to 0.91], P = 0.019). In multivariate analysis, disease free interval > 2 years (P = 0.036), a sum of metastatic sites < 3 (P = 0.034), and BP treatments (P = 0.007) were significant factors for survival in HR negative patients.Bisphosphonate treatment can result in a survival benefit in metastatic breast cancer patients with HR negative tumors.Bone metastases are common in patients with advanced breast cancer. The median survival time after the diagnosis of bone metastases is approximately two years, although it may increase with new treatment regimens [1]. As patients survive longer, the incidence of associated problems with metastatic bone disease (MBD), such as pathologic fracture or spinal cord compression, increases, and these complications may substantially reduce a patient's quality of life [1,2]. Over the past decade, bisphosphonates (BPs) have become the standard therapy for breast cancer patients with bone metastasis. It is now clear that the bisphosphonates reduce both the symptoms and complications of bone involvement [3]. In addition, the anti-tumor activities of BPs have been explored, particularly with zoledronate and pamidronate, through in-vitro as well as in-vivo animal studies [4-6]. These preclinical studies showed that BPs could reduce visceral metastasis as well as bone metastas
Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea
Ro Jungsil,Park Sohee,Kim Sung-,Kim Tae
BMC Cancer , 2012, DOI: 10.1186/1471-2407-12-322
Abstract: Background To evaluate efficacy in patients with brain metastasis (BM) on entry into the lapatinib expanded access program (LEAP). Methods LEAP is a worldwide, single-arm, open-label study. HER2-positive, locally-advanced or metastatic breast cancer patients with progression after an anthracycline, taxane, and trastuzumab were eligible. Patients received capecitabine 2000 mg/m2 daily in two divided doses, days 1–14, every 21 days and lapatinib 1250 mg once daily. Results Among 186 patients enrolled in 6 Korean centers, 58 had BM. Progression-free survival (PFS) was 18.7 weeks in patients with BM and 19.4 weeks without BM (P = 0.88). In patients with BM, brain response was synchronized with systemic responses (P = 0.0001). Overall survival (OS) was 48.9 weeks in patients with BM and 64.6 weeks without BM (P = 0.23). Multivariable analysis found hormone receptor positivity (P = 0.003) and clinical benefit rate (CBR) of combined systemic and brain disease (P < 0.0001) significantly associated with prolonged brain PFS, and CBR of combined systemic and brain disease (P = 0.03) and longer trastuzumab use (P = 0.047) associated with prolonged OS in patients with BM; prior capecitabine did not affect PFS or OS in patients with BM. Conclusion Lapatinib plus capecitabine is equally effective in patients with or without BM. Trial registration ClinicalTrials.gov (NCT00338247)
Progranulin as a Prognostic Biomarker for Breast Cancer Recurrence in Patients Who Had Hormone Receptor-Positive Tumors: A Cohort Study
Dong Hoe Koo, Cheol-Young Park, Eun Sook Lee, Jungsil Ro, Sang Woo Oh
PLOS ONE , 2012, DOI: 10.1371/journal.pone.0039880
Abstract: Background Progranulin (PGRN) is considered to play an important role in breast cancer tumorigenesis and in inhibiting tamoxifen-induced apoptosis. We aimed to determine whether PGRN levels are associated with breast cancer recurrence after curative surgery. Methodology/Principal Findings We evaluated the associations between preoperative serum PGRN levels and breast cancer recurrence in a cohort of 697 newly diagnosed breast cancer patients who underwent curative surgery between April 2001 and December 2004. The mean age ± standard deviation (SD) was 46±9.8 years, and all patients with hormone receptor (HR)-positive tumors received adjuvant tamoxifen therapy. At a median follow-up of 62.2 months (range, 2.9–98.2), 89 patients (12.8%) had experienced a recurrence and 51 patients (7.3%) had died. In the HR-positive group, serum PGRN levels were associated with recurrence according to the log-rank test for trend (p for trend = 0.049). There was no association between PGRN levels and recurrence in the HR-negative group (p for trend = 0.658). Adjusted hazard ratios, including possible confounders, revealed a linear relationship between serum PGRN levels and recurrence in the HR-positive group (p for trend = 0.049), and this association was further strengthened after excluding patients who had no lymph node metastasis (p for trend = 0.038). Conclusions/Significance Serum PGRN levels were clinically significant for predicting recurrence in patients with HR-positive breast cancer during adjuvant tamoxifen therapy.
Breast cancer subtypes and survival in patients with brain metastases
Byung-Ho Nam, Sun Kim, Hye-Sook Han, Youngmee Kwon, Keun Lee, Tae Kim, Jungsil Ro
Breast Cancer Research , 2008, DOI: 10.1186/bcr1870
Abstract: Retrospective survival analyses were performed in 126 BM patients from 805 MBC patients treated at the National Cancer Center between August 2001 and April 2006, according to clinical characteristics, breast cancer subtypes, and receipt of trastuzumab. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth receptor-2 (HER2) statuses were tested by immunohistochemical (IHC) staining, and HER2 FISH analysis conducted for IHC 2+.The proportion of HER2+/ER- (29% vs 16%) and triple-negative (37% vs 25%) tumors was higher in the 126 BM patients than those without BM. While median survival after recurrence was longer in patients with luminal A disease (median survival of luminal A vs luminal B vs HER2+/ER- vs triple-negative: p = 0.0246; 39.6 vs 27.4 vs 20.9 vs 15.5 months), survival was shorter from BM to death in luminal A and triple negatives (median survival: p = 0.0113; 4.0 vs 9.2 vs 5.0 vs 3.4 months). Receipt of trastuzumab after BM was a significant variable for survival in HER2+ patients. Multivariate analyses identified ER-negative, HER2-negative, or triple-negative, as well as older age, presence of leptomeningeal disease, and three or more extracranial disease sites, as poor prognostic factors for survival after BM.MBC patients who developed BM had higher proportions of triple-negative and HER2+/ER- tumor status. Triple receptor status is a useful prognostic marker for predicting survival after BM in metastatic breast cancer patients.Brain metastases (BM) clinically present in up to 16% of all metastatic breast cancers (MBC), although autopsy series reveal approximately twice as many cases (34%) [1,2]. Of the patients with BM at autopsy, 19% are identified as having leptomeningeal disease (LMD) [1]. Prognosis of BM is extremely poor, and the median survival of BM patients ranges from 3 to 6 months [3], as it is usually a late event of systemic disease. The general medical condition is often deteriorated by progressive neurological disabi
Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study
Sang Oh, Cheol-Young Park, Eun Lee, Yeong Yoon, Eon Lee, Sang Park, Yuil Kim, Nak Sung, Young Yun, Keun Lee, Han Kang, Youngmee Kwon, Jungsil Ro
Breast Cancer Research , 2011, DOI: 10.1186/bcr2856
Abstract: We examined associations between breast cancer recurrence and adiponectin, leptin, insulin resistance, and metabolic syndrome (MetS) in a cohort of 747 patients from 2001 to 2004.Adjusted hazard ratios showed an inverse trend across the quartiles for serum adiponectin concentration in estrogen receptor (ER)/progesterone receptor (PR) -negative patients (P for trend = 0.027) but not in ER/PR-positive patients. Compared to the highest quartile for adiponectin level, the lowest quartile showed a hazard ratio of 2.82 (1.03 to 7.68). Homeostasis model assessment for insulin resistance (HOMA-IR) showed a positive trend for recurrence in the ER/PR-negative group (P for trend = 0.087) and a negative trend in the ER/PR-positive group (P for trend = 0.081). Leptin did not show any associations (P for trend >0.05). A linear trend was observed with the number of components of MetS in ER/PR-negative patients (P for trend = 0.044). This association disappeared when adjusted for adiponectin and HOMA-IR.Adiponectin and HOMA-IR have prognostic significance in breast cancer recurrence and interventions related to these factors may protect against recurrence in ER/PR-negative patients. These findings were not observed in the case of ER/PR-positive patients. Further evaluation of these insignificant associations is needed because it might be biased by adjuvant chemotherapy or other confounders.Recent studies have suggested that breast cancer is associated with insulin resistance [1-5], metabolic syndrome (MetS) [4,6], and adipokine levels [7-15]. However, the clinical significance of these findings remains controversial because only limited human data have been published, and inconsistent results have been obtained from these data [1-4,6-16]. Another weakness of previous studies is that most were conducted under cross-sectional designs that failed to establish temporal relationships for causality; in these studies, risk factors were assessed at the same time or after the study outcomes
Fatty fish and fish omega-3 fatty acid intakes decrease the breast cancer risk: a case-control study
Jeongseon Kim, Sun-Young Lim, Aesun Shin, Mi-Kyung Sung, Jungsil Ro, Han-Sung Kang, Keun Lee, Seok-Won Kim, Eun-Sook Lee
BMC Cancer , 2009, DOI: 10.1186/1471-2407-9-216
Abstract: We recruited 358 incident breast cancer patients and 360 controls with no history of malignant neoplasm from the National Cancer Center Hospital between July 2007 and April 2008. The study participants were given a 103-item food intake frequency questionnaire to determine their dietary consumption of fish (fatty and lean fish) and ω-3 fatty acids derived from fish (eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA)).Using a multivariate logistic regression model, high intake of fatty fish was associated with a reduced risk for breast cancer in both pre- and postmenopausal women (OR [95% CI] for highest vs. lowest intake quartiles, p for trend: 0.19 [0.08 to 0.45], p < 0.001 for premenopausal women, 0.27 [0.11 to 0.66], p = 0.005 for postmenopausal women). Similarly, reductions in breast cancer risk were observed among postmenopausal subjects who consumed more than 0.101 g of EPA (OR [95% CI]: 0.38 [0.15 to 0.96]) and 0.213 g of DHA (OR [95% CI]: 0.32 [0.13 to 0.82]) from fish per day compared to the reference group who consumed less than 0.014 g of EPA and 0.037 g of DHA per day. Among premenopausal women, there was a significant reduction in breast cancer risk for the highest intake quartiles of ω-3 fatty acids (ORs [95% CI]: 0.46 [0.22 to 0.96]), compared to the reference group who consumed the lowest quartile of intake.These results suggest that high consumption of fatty fish is associated with a reduced risk for breast cancer, and that the intake of ω-3 fatty acids from fish is inversely associated with postmenopausal breast cancer risk.Breast cancer is one of the most prevalent cancers in the world including South Korea [1,2]. The second report by the World Cancer Research Fund and the American Institute for Cancer Research indicates that food and nutrition may affect the status of hormones that can modify breast cancer risk [3]. Among the dietary factors, there has been mixed evidence regarding the impact of fish and ω-3 fatty acid intake on breast ca
Association of Polymorphisms and Haplotypes in the Insulin-Like Growth Factor 1 Receptor (IGF1R) Gene with the Risk of Breast Cancer in Korean Women
Han-Sung Kang, Sei Hyun Ahn, Siddhartha Kumar Mishra, Kyeong-Man Hong, Eun Sook Lee, Kyung Hwan Shin, Jungsil Ro, Keun Seok Lee, Mi Kyung Kim
PLOS ONE , 2014, DOI: 10.1371/journal.pone.0084532
Abstract: The insulin-like growth factor (IGF) signaling pathway plays an important role in cancer biology. The IGF 1 receptor (IGF1R) overexpression has been associated with a number of hematological neoplasias and solid tumors including breast cancer. However, molecular mechanism involving IGF1R in carcinogenic developments is clearly not known. We investigated the genetic variations across the IGF1R polymorphism and the risk of breast cancer risk in Korean women. A total of 1418 individuals comprising 1026 breast cancer cases and 392 age-matched controls of Korean were included for the analysis. Genomic DNA was extracted from whole blood and single nucleotide polymorphisms (SNPs) were analyzed on the GoldenGate Assay system by Illumina’s Custom Genetic Analysis service. SNPs were selected for linkage disequilibrium (LD) analysis by Haploview. We genotyped total 51 SNPs in the IGF1R gene and examined for association with breast cancer. All the SNPs investigated were in Hardy-Weinberg equilibrium. These SNPs tested were significantly associated with breast cancer risk, after correction for multiple comparisons by adjusting for age at diagnosis, BMI, age at menarche, and age at first parturition. Among 51 IGF1R SNPs, five intron located SNPs (rs8032477, rs7175052, rs12439557, rs11635251 and rs12916884) with homozygous genotype (variant genotype) were associated with decreased risk of breast cancer. Fisher’s combined p-value for the five SNPs was 0.00032. Three intron located SNPs with heterozygous genotypes also had decreased risk of breast cancer. Seven of the 51 IGF1R SNPs were in LD and in one haplotype block, and were likely to be associated with breast cancer risk. Overall, this case-control study demonstrates statistically significant associations between breast cancer risk and polymorphisms in IGF1R gene.
Protein and lipid MALDI profiles classify breast cancers according to the intrinsic subtype
Han Kang, Seok Lee, Young Park, Young Jeon, Jeong Lee, So-Youn Jung, In Park, Seok Jang, Hye Park, Chong Yoo, Seok Park, Sang Han, Kwang Kim, Young Kim, Jungsil Ro, Hark Kim
BMC Cancer , 2011, DOI: 10.1186/1471-2407-11-465
Abstract: Thirty-four pairs of frozen, resected breast cancer and adjacent normal tissue samples were analyzed using histology-directed, MALDI MS analysis. Sinapinic acid and 2,5-dihydroxybenzoic acid/α-cyano-4-hydroxycinnamic acid were manually deposited on areas of each tissue section enriched in epithelial cells to identify lipid profiles, and mass spectra were acquired using a MALDI-time of flight instrument.Protein and lipid profiles distinguish cancer from adjacent normal tissue samples with the median prediction accuracy of 94.1%. Luminal, HER2+, and triple-negative tumors demonstrated different protein and lipid profiles, as evidenced by permutation P values less than 0.01 for 0.632+ bootstrap cross-validated misclassification rates with all classifiers tested. Discriminatory proteins and lipids were useful for classifying tumors according to the intrinsic subtype with median prediction accuracies of 80.0-81.3% in random test sets.Protein and lipid profiles accurately distinguish tumor from adjacent normal tissue and classify breast cancers according to the intrinsic subtype.Proteomics research is actively being performed to find biomarkers for common solid tumors [1,2] including breast cancer [3-5]. Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry (MS) has been demonstrated to be useful for histological classification [6-10] and outcome prediction [11] of common solid tumors.In this approach, thin sections of frozen tissues are obtained from surgical resections or biopsies and mass spectra are obtained from discrete locations on the tissue. In a study of human breast cancer samples, protein profiles obtained from histology-directed MALDI MS differentiate invasive breast cancers from ductal carcinoma in situ and normal breast epithelium [12]. In another report, MALDI imaging MS classified breast cancer tissue specimens according to HER2 status [13].Accumulating evidence suggests that alteration in lipid composition is associated with breast carcin
The invasive lobular carcinoma as a prototype luminal A breast cancer: A retrospective cohort study
So-Youn Jung, Junsoo Jeong, Seung-Ho Shin, Youngmee Kwon, Eun-A Kim, Kyoung Ko, Kyung Shin, Keun Lee, In Park, Seeyoun Lee, Seok Kim, Han-Sung Kang, Jungsil Ro
BMC Cancer , 2010, DOI: 10.1186/1471-2407-10-664
Abstract: We assessed the clinical characteristics and outcomes of 83 Korean patients (2.8%) with ILC for comparison with 2,833 (97.2%) with the invasive ductal carcinoma (IDC), including 1,088 (37.3%) with the luminal A subtype (LA-IDC).The mean age of all patients was 48.2 years, with no significant differences among the groups. Compared to IDC, ILC showed a larger tumor size (≥T2, 59.8% vs. 38.8%, P = 0.001), a lower histologic grade (HG 1/2, 90.4% vs. 64.4%, P < 0.001), more frequent estrogen receptor positive (90.4% vs. 64.4%, P < 0.001), progesterone receptor positive (71.1% vs. 50.1%, P < 0.001) and HER2 negative (97.5% vs. 74.6%, P < 0.001) status, and lower Ki-67 expression (10.3% ± 10.6% vs. 20.6% ± 19.8%, P < 0.001), as well as being more likely to be of the luminal A subtype (91.4% vs. 51.2%, P < 0.001). Six (7.2%) ILC and 359 (12.7%) IDC patients developed disease recurrence, with a median follow-up of 56.4 (range 4.9-136.6) months. The outcome of ILC was close to LA-IDC (HR 0.77 for recurrence, 95% CI 0.31-1.90, P = 0.57; HR 0.75 for death, 95% CI 0.18-3.09, P = 0.70) and significantly better than for the non-LA-IDC (HR 1.69 for recurrence, 95% CI 1.23-2.33, P = 0.001; HR 1.50 for death, 95% CI 0.97-2.33, P = 0.07).ILC, a rare histologic type of breast cancer in Korea, has distinctive clinicopathological characteristics similar to those of LA-IDC.The invasive lobular carcinoma (ILC), known to be the second most common histologic subtype of invasive breast cancer following the invasive ductal carcinoma (IDC), constitutes 8-14% of all breast cancers in most Western reports [1-3]. However, in Asia it appears to be very low, accounting for only 2-4% in Korea [4-6] and 1-4% in Japan [7,8].Previous studies have demonstrated distinctive clinical and biologic characteristics for ILC as compared with IDC. For example, it is more likely to occur in older patients, be larger in size, be estrogen receptor (ER) and progesterone receptor (PgR) positive and have low to absent
Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
Sae-Won Han, Yongjun Cha, Agnes Paquet, Weidong Huang, Jodi Weidler, Yolanda Lie, Thomas Sherwood, Michael Bates, Mojgan Haddad, In Hae Park, Do-Youn Oh, Keun Seok Lee, Seock-Ah Im, Yung-Jue Bang, Jungsil Ro, Tae-You Kim
PLOS ONE , 2012, DOI: 10.1371/journal.pone.0039943
Abstract: Background Lapatinib plus capecitabine is an effective treatment option for trastuzumab-refractory HER2-positive metastatic breast cancer. We have investigated the correlation between quantitative measures of HER2, p95HER2, and HER3 and treatment outcomes using lapatinib and capecitabine. Methods Total HER2 (H2T), p95HER2 (p95), and total HER3 (H3T) expression were quantified in formalin-fixed paraffin-embedded samples using the VeraTag assays. Patients received lapatinib and capecitabine treatment following trastuzumab failure according to the Lapatinib Expanded Access Program. The association between the protein expression levels and clinical outcomes was analyzed. Results A total of 52 patients were evaluable. H2T level was significantly higher in responders (median 93.49 in partial response, 47.66 in stable disease, and 17.27 in progressive disease; p = 0.020). Longer time-to-progression (TTP) was observed in patients with high H2T [p = 0.018, median 5.2 months in high (>14.95) vs. 1.8 in low (<14.95)] and high H3T [p = 0.017, median 5.0 months in high (>0.605) vs. 2.2 in low (<0.605)]. Patients having both high H2T and high H3T had significantly longer TTP [adjusted hazard ratio (HR) 0.38 (95% CI 0.20–0.73), p = 0.004] and overall survival [adjusted HR 0.46 (95% CI 0.24–0.89), p = 0.020]. No significant association between p95 and response or survival was observed. Conclusions These data suggest a correlation between high HER2 and high HER3 expression and treatment outcome, while no significant difference was observed between clinical outcome and p95 expression level in this cohort of HER2-positive, trastuzumab-refractory metastatic breast cancer patients treated with lapatinib and capecitabine.
Page 1 /702
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.